Brain cancer results, PD-1 potential boost Agenus
This article was originally published in Scrip
Executive Summary
Agenus's stock jumped 10.3% after the company said its autologous cancer vaccine Prophage provided a significant increase in brain cancer survival rates and showed potential for improved efficacy in combination with programmed cell death-1 (PD-1) receptor antagonists in an open-label Phase II clinical trial.